By Fineline Cube 
KANTE (Shenzhen) Biotechnology Co., Ltd (“Kante-bio”) announced that it has received a Category III medical device license from the National Medical Products Administration (NMPA) for its Yilijia early detection test kit for pancreatic cancer. This marks a significant milestone in the early diagnosis of pancreatic cancer.
Innovative miRNA-Based Detection
Yilijia is a 4-microRNA test kit utilizing fluorescence PCR technology. It stands out as the world’s first early and precise detection product for pancreatic cancer approved based on serum miRNA multi-target detection technology. By leveraging original and specific tumor biomarkers, Yilijia offers a more accurate and effective method for early pancreatic cancer detection, addressing a critical gap in the global landscape of pancreatic cancer diagnosis.
Clinical Significance
The approval of Yilijia reflects the growing recognition of miRNA-based detection methods in oncology. This innovative approach not only enhances early diagnosis capabilities but also provides healthcare professionals with a powerful tool to improve patient outcomes in pancreatic cancer management.-Fineline Info & Tech